Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with pimecrolimus 1% (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 6 weeks · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.1% changes adverse effects ‐ 6 weeks compared with pimecrolimus 1% (very low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ application site reaction · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ application site reaction compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ burning compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ itching · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ itching compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ erythema · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ erythema compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Partial renal remission · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Stable kidney function · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Complete renal remission · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review